Literature DB >> 8897436

Botulinum neurotoxins: mechanism of action and therapeutic applications.

C Montecucco1, G Schiavo, V Tugnoli, D de Grandis.   

Abstract

Recent studies have led to the discovery of the molecular lesions in motor neurons caused by botulinum neurotoxins. These neurotoxins are metalloproteinases that enter the cytosol and very specifically cleave protein components of the neuroexocytosis apparatus. Consequently, acetylcholine cannot be released and the muscle is paralysed. For this reason, botulinum neurotoxins are increasingly being used to treat a variety of conditions where a functional paralysis of neuromuscular junctions is useful as therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897436     DOI: 10.1016/1357-4310(96)84845-3

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  11 in total

1.  Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Authors:  Michael R Baldwin; William H Tepp; Christina L Pier; Marite Bradshaw; Mengfei Ho; Brenda A Wilson; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Management of movement disorders in glutaryl-CoA dehydrogenase deficiency: anticholinergic drugs and botulinum toxin as additional therapeutic options.

Authors:  A P Burlina; G Zara; G F Hoffmann; J Zschocke; A B Burlina
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

3.  Characterization of a cytotoxic factor in culture filtrates of Serratia marcescens.

Authors:  Kent B Marty; Christopher L Williams; Linda J Guynn; Michael J Benedik; Steven R Blanke
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

4.  Short-term autonomic denervation of the atria using botulinum toxin.

Authors:  Seil Oh; Eue-Keun Choi; Yun-Shik Choi
Journal:  Korean Circ J       Date:  2010-08-31       Impact factor: 3.243

5.  Sacral neuromodulation: Therapy evolution.

Authors:  Jannah H Thompson; Suzette E Sutherland; Steven W Siegel
Journal:  Indian J Urol       Date:  2010-07

Review 6.  Botulinum neurotoxin for pain management: insights from animal models.

Authors:  Flaminia Pavone; Siro Luvisetto
Journal:  Toxins (Basel)       Date:  2010-12-21       Impact factor: 4.546

7.  Temporary Suppression of Cardiac Ganglionated Plexi Leads to Long-Term Suppression of Atrial Fibrillation: Evidence of Early Autonomic Intervention to Break the Vicious Cycle of "AF Begets AF".

Authors:  Li-Wei Lo; Hung-Yu Chang; Benjamin J Scherlag; Yenn-Jiang Lin; Yu-Hui Chou; Wei-Lun Lin; Shih-Ann Chen; Sunny S Po
Journal:  J Am Heart Assoc       Date:  2016-07-05       Impact factor: 5.501

8.  Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons.

Authors:  Charles Joussain; Olivier Le Coz; Andrey Pichugin; Peggy Marconi; Filip Lim; Mariaconcetta Sicurella; Andrea Salonia; Francesco Montorsi; Francisco Wandosell; Keith Foster; François Giuliano; Alberto L Epstein; Alejandro Aranda Muñoz
Journal:  Toxins (Basel)       Date:  2019-02-19       Impact factor: 4.546

9.  Refractory overactive bladder: Beyond oral anticholinergic therapy.

Authors:  Ronald W Glinski; Steven Siegel
Journal:  Indian J Urol       Date:  2007-04

10.  Substrate binding mode and its implication on drug design for botulinum neurotoxin A.

Authors:  Desigan Kumaran; Richa Rawat; S Ashraf Ahmed; Subramanyam Swaminathan
Journal:  PLoS Pathog       Date:  2008-09-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.